Key clinical point: The Eutos long-term survival (ELTS) score appeared better at predicting overall survival (OS) in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), redefining the risk stratification obtained with the Sokal score. Patients defined as high risk by ELTS showed poorer OS, thereby warranting treatment intensification and close monitoring.
Major finding: A prognostic refinement was observed from the Sokal to the ELTS score in high and intermediate Sokal risk patients. In the high-risk Sokal group, 3-year OS ranged from 94.8% to 82.4% for patients considered at ‘true’ high risk. In the intermediate Sokal risk group, 3-year OS of high-risk patients was only 70.7% vs. 95.4% for low-risk and 87.9% for ‘true’ intermediate-risk patients.
Study details: Findings are from the analysis of 1,206 patients with CML from the GIMEMA observational study. Patients were treated with either imatinib (n=608) or second-generation TKIs, dasatinib, or nilotinib (n=598).
Disclosures: No source of funding was identified. Some investigators including the lead author reported honoraria from various pharmaceutical companies.
Source: Breccia M et al. Leukemia. 2021 May 17. doi: 10.1038/s41375-021-01292-4 .